Information Provided By: 
Fly News Breaks for August 14, 2017
EGLT
Aug 14, 2017 | 07:50 EDT
Cantor analyst Brandon Folkes, assumed coverage of Egalet with a $7 price target and an Overweight rating. He says that the company is poised "to benefit from the need to reduce opioid abuse" while lowering patients' pain. The analyst says that a "strong launch" of the company's Arymo ER drug could spur many more investors to buy its shares.
News For EGLT From the Last 2 Days
There are no results for your query EGLT
